|

AI-081 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Bispecific anti-PD-1/VEGF

Pipeline

Phase 1/2: 1

Top Sponsors

  • OncoC4, Inc.1

Indications

  • Advanced Solid Tumor1
  • Cancer1

Birmingham, Alabama1 trial

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.